The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

U.S.-listed shares of Verona Pharma ( VRNA) soared to an all-time high Wednesday after Merck ( MRK) agreed to pay about $10 ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to ...

We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...